Skip to main content
//empty //empty
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Helius Medical Technologies to Present at the Virtual Summer Summit on June 9th

GlobeNewswire - Fri Jun 5, 6:05AM CDT

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM.TO) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced that management will participate in the Virtual Summer Summit, which is being held from June 9th-12th. Management will present on Tuesday, June 9th at 4:30 p.m. Eastern Time.

A live audio webcast of the presentation will be provided under the 'Events' section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. An archive of the webcast will be available for replay following the conference.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS(TM)). For more information, visit www.heliusmedical.com.

About the PoNS(TM) Device and PoNS Treatment(TM)

The Portable Neuromodulation Stimulator (PoNS) is an authorized class II, non-implantable medical device authorized for sale in Canada. PoNS is intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy and indicated as a short term treatment (14 weeks) chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The PoNS is an investigational medical device in the United States, the European Union, and Australia, and is currently under review for clearance by the AUS Therapeutic Goods Administration. PoNS Treatment is currently not commercially available in the United States, the European Union or Australia.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.

Mike Piccinino, CFA

investorrelations@heliusmedical.com

https://ml.globenewswire.com/media/f66facdd-4e51-49b4-b66a-d806d02134d5/small/helius-jpg.jpg

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies